Clinical Trial Detail

NCT ID NCT03729245
Title A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Nektar Therapeutics
Indications

renal cell carcinoma

Therapies

Cabozantinib + Sunitinib

Nivolumab + NKTR-214

Age Groups: adult senior

No variant requirements are available.